natgillin/translations-raw huggingface dataset:
In the Einstein DVT study (see Table 3) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)).
V kliničnem preskušanju Einstein DVT (glejte preglednico 3) se je v primarnem končnem izidu pokazalo, da je rivaroksaban enakovreden zdravljenju z enoksaparinom/antagonisti vitamina K (p < 0,0001 (test neinferiornosti); razmerje tveganja: 0,680 (0,443 - 1,042), p = 0,076 (test superiornosti)).
In the Einstein DVT study (see Table 5) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p < 0.0001 (test for non-inferiority); hazard ratio: 0.680 (0.443 - 1.042), p=0.076 (test for superiority)).
V kliničnem preskušanju Einstein DVT (glejte preglednico 5) se je v primarnem končnem izidu pokazalo, da je rivaroksaban enakovreden zdravljenju z enoksaparinom/antagonisti vitamina K (p < 0,0001 (test neinferiornosti); razmerje tveganja: 0,680 (0,443 - 1,042), p = 0,076 (test superiornosti)).
In the Einstein Extension study (see Table 6) rivaroxaban was superior to placebo for the primary and secondary efficacy outcomes.
V kliničnem preskušanju Einstein Extension (glejte preglednico 6) je bil rivaroksaban boljši od placeba glede na primarni in sekundarni izid učinkovitosti.
In the Einstein PE study (see Table 4) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); hazard ratio: 1.123 (0.749 – 1.684)).
V kliničnem preskušanju Einstein PE (glejte preglednico 4) je bilo prikazano, da je rivaroksaban neinferioren v primerjavi z zdravljenjem z enoksaparinom/antagonisti vitamina K za primarni izid učinkovitosti (p = 0.0026 (test za neinferiornost); razmerje tveganja: 1,123 (0,749 - 1,684)).
In the Einstein PE study (see Table 6) rivaroxaban was demonstrated to be non-inferior to enoxaparin/VKA for the primary efficacy outcome (p=0.0026 (test for non-inferiority); hazard ratio: 1.123 (0.749 – 1.684)).
V kliničnem preskušanju Einstein PE (glejte preglednico 6) je bilo prikazano, da je rivaroksaban neinferioren v primerjavi z zdravljenjem z enoksaparinom/antagonisti vitamina K za primarni izid učinkovitosti (p = 0.0026 (test za neinferiornost); razmerje tveganja: 1,123 (0,749 - 1,684)).
In the elderly frequencies were similar, except for myalgia, headache and injection site pain which were classified as ‘common’.
Pri starejših je bila pogostnost podobna, z izjemo mialgije, glavobola in bolečine na mestu injiciranja, ki so bili razvrščeni kot ‘pogosti’.
In the elderly population (≥ 65 years of age) 4 of 5 patients (80.0%) achieved CR/CRh* within 2 treatment cycles (see section 4.8 for safety in elderly).
V starejši populaciji (starost ≥ 65 let) so 4 od 5 bolnikov (80,0 %) dosegli CR/CRh* v 2 ciklusih zdravljenja (glejte poglavje 4.8 za informacije o varnosti pri starejših osebah).
In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/or in patients with intercurrent events, hyperkalaemia may be fatal.
Hiperkaliemija je lahko smrtna pri starejših bolnikih, bolnikih z zmanjšanim delovanjem ledvic, sladkornih bolnikih, bolnikih, sočasno zdravljenih z drugimi zdravili, ki lahko povečajo koncentracijo kalija, in/ali bolnikih s sočasnimi boleznimi.
In the elderly, progressive deterioration of renal function may lead to a steady decrease in insulin requirements.
Pri starejših lahko napredujoče slabšanje delovanja ledvic povzroči stalno zmanjševanje potrebe po insulinu.
In the ELECTRON study (N = 11), the duration of peginterferon alfa ranged from 4-12 weeks in combination with sofosbuvir + ribavirin.
V študiji ELECTRON (N = 11) je bil razpon trajanja zdravljenja s peginterferonom alfa 4–12 tednov v kombinaciji s sofosbuvirjem + ribavirinom.
In the eligible population, the subgroup analyses according to the prior cisplatin use versus BSC on overall survival (OS) showed a HR (95% CI) = [0.64 (0.40 – 1.03); p=0.0821] in the absence of prior cisplatin, and a HR (95% CI) = [0.80 (0.60 – 1.06); p=0.1263] in the presence of prior cisplatin.
V populaciji primernih bolnikov je analiza podskupin s predhodnim zdravljenjem s cisplatinom in NPO za skupno preživetje pokazala razmerje ogroženosti HR (95-odstotni IZ) = [0,64 (0,40 – 1,03); p=0,0821] brez predhodnega cisplatina in HR (95-odstotni IZ) = [0,80 (0,60 – 1,06); p=0,1263] po predhodno uporabljenem cisplatinu.
In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction).
V skupini, ki je prejemala enoksaparin/antagoniste vitamina K ni bilo jasnega razmerja med povprečno vrednostjo TTR (Time in Target INR v mejah 2,0 do 3,0) pri enako velikih tercilih in incidenci ponovne VTE (p = 0,082 za interakcije).
In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (p=0.082 for interaction).
V skupini, ki je prejemala enoksaparin/antagoniste vitamina K ni bilo jasnega razmerja med povprečno vrednostjo TTR (Time in Target INR v mejah od 2,0 do 3,0) pri enako velikih tercilih in incidenci ponovne VTE (p = 0,082 za interakcije).
In the enoxaparin/VKA group, there was no clear relation between the level of mean centre TTR (Time in Target INR Range of 2.0 – 3.0) in the equally sized tertiles and the incidence of the recurrent VTE (P=0.932 for interaction).
V skupini, ki je prejemala enoksaparin/antagoniste vitamina K, ni bilo jasnega razmerja med povprečno vrednostjo TTR (Time in Target INR v mejah od 2,0 do 3,0) pri enako velikih tercilih in incidenco ponovne VTE (p = 0,932 za interakcije).
In the ERT- naïve trial and open label extension, renal function remained stable for 3 years of treatment with Galafold.
Pri ERT-naivnem preskušanju in odprtem podaljšanem preskušanju je delovanje ledvic ostalo stabilno 3 leta od začetka zdravljenja z zdravilom Galafold.
In the ERT- naïve trial, Galafold showed statistically significant reductions in plasma lyso-Gb3 concentrations and kidney interstitial capillary GL-3 inclusions in patients with amenable mutations.
Pri ERT-naivnem preskušanju se je pri bolnikih z odzivnimi mutacijami ob uporabi zdravila Galafold plazemska koncentracija lizo-Gb3 statistično značilno zmanjšala, prav tako je bilo manj vključkov GL- 3 v intersticijskih kapilarah ledvic.
In the ERT-experienced trial, following 18 months of treatment with Galafold there was a statistically significant decrease in LVMi (p< 0.05).
V ERT-izkušenem preskušanju se je po 18-mesečnem zdravljenju z zdravilom Galafold LVMi statistično značilno zmanjšal (p < 0,05).
In the ERT-experienced trial, plasma lyso-Gb3 levels remained low and stable for up to 18 months in patients with amenable mutations switched from ERT to Galafold, and in patients remaining on ERT.
Pri ERT-izkušenem preskušanju je pri bolnikih z odzivnimi mutacijami, ki so z ERT prešli na zdravilo Galafold, ter pri bolnikih, ki so ostali na ERT, plazemska koncentracija lizo-Gb3 ostala nizka in stabilna do 18 mesecev.
In the ERT-experienced trial, renal function remained stable for up to 18 months of treatment with Galafold.
Pri ERT-izkušenem preskušanju je delovanje ledvic ostalo stabilno do 18 mesecev od začetka zdravljenja z zdravilom Galafold.
In the ERT-naïve trial, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that treatment with Galafold was associated with statistically significant (p<0.05) improvements versus placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with symptoms at baseline.
Pri ERT-naivnem preskušanju so analize lestvice za oceno gastrointestinalnih simptomov pokazale, da je bilo zdravljenje z zdravilom Galafold povezano s statistično pomembnim (p < 0,05) izboljšanjem v primerjavi s placebom na področju diareje od izhodišča do 6. meseca ter na področju refluksa pri bolnikih s simptomi v izhodišču.
In the ERT-naïve trial, Galafold resulted in a statistically significant decrease in LVMi (p< 0.05); the mean change from baseline in LVMi at Month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27).
Pri ERT-naivnem preskušanju je zdravilo Galafold povzročilo statistično značilno zmanjšanje LVMi (p < 0,05); srednja sprememba od izhodiščnega LVMi v 18. do 24. mesecu je bila –7,7 (95-% CI: – 15,4, –0,01; n = 27).
In the European study, a total of 51 subjects with primary immunodeficiency syndromes aged between 3 and 60 years old were treated with Hizentra for up to 41 weeks.
V evropski študiji so skupno 51 preiskovancev s sindromi primarne imunske pomanjkljivosti, starih med 3 in 60 let, zdravili z zdravilom Hizentra v obdobju do 41 tednov.
In the evening, take 600 milligram PREZISTA together with 100 milligram ritonavir.
Zvečer vzemite 600 miligramov zdravila PREZISTA skupaj s 100 miligrami ritonavirja.
In the evening, take one 600 milligram PREZISTA tablet together with 100 milligram ritonavir.
Zvečer vzemite eno 600-miligramsko tableto zdravila PREZISTA skupaj s 100 miligrami ritonavirja.
In the evening, take two 300 milligram PREZISTA tablets together with 100 milligram ritonavir.
Zvečer vzemite dve 300-miligramski tableti PREZISTA skupaj s 100 miligrami ritonavirja.
In the event a patient does still not respond when treated with the maximum dose of hydroxycarbamide (35 mg/kg b.w./day) over three to six months, permanent discontinuation of Siklos should be considered.
Če se bolnik še vedno ne odziva, ko zdravljenje z najvišjim odmerkom hidroksikarbamida (35 mg/kg TM/dan) traja že tri do šest mesecev, je treba razmisliti o trajni prekinitvi jemanja zdravila Siklos.
In the event of a change in COPD intensity while the patient is being treated with aclidinium bromide so that the patient considers additional rescue medication is required, a re-evaluation of the patient and the patients’ treatment regimen should be conducted.
Če je sprememba intenzivnosti KOPB med zdravljenjem bolnika z aklidinijevim bromidom tolikšna, da bolnik razmišlja o dodatnem reševalnem zdravilu, je treba ponovno ovrednotiti režim zdravljenja bolnika.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Sildenafil Teva and when you did.
V primeru zdravstvene obravnave morate povedati zdravniku, farmacevtu ali medicinki sestri, da ste vzeli zdravilo Sildenafil Teva in kdaj ste ga vzeli.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken VIAGRA and when you did.
V primeru nujne zdravstvene obravnave morate povedati zdravniku, farmacevtu ali medicinski sestri, da ste vzeli zdravilo VIAGRA in kdaj ste ga vzeli.
In the event of a medical emergency, you should tell your doctor, pharmacist or nurse that you have taken Vizarsin and when you did.
Če pride do nujne zdravstvene obravnave, morate zdravniku, farmacevtu ali medicinski sestri, povedati, da ste vzeli zdravilo Vizarsin in kdaj ste ga vzeli.
In the event of a planned transfusion blood transfusion centres should be notified of this interference with indirect antiglobulin tests (see section 4.5).
V primeru načrtovane transfuzije je treba transfuzijski center obvestiti o možnosti navedenega vpliva na rezultate indirektnih antiglobulinskih testov (glejte poglavje 4.5).
In the event of a planned transfusion, the HCPs should notify blood transfusion centres about the interference with indirect antiglobulin tests;
V primeru načrtovane transfuzije je treba transfuzijski center obvestiti o možnosti navedenega vpliva na rezultate indirektnih antiglobulinskih testov.
In the event of a possible overdose you should contact your doctor immediately.
V primeru prevelikega odmerka se takoj posvetujte z vašim zdravnikom.
In the event of a possible overdose you should contact your doctor immediately.
V primeru prevelikega odmerka se takoj posvetujte z zdravnikom.
In the event of a second clinically significant infection, clofarabine treatment should be withheld until the infection is clinically controlled and may be reinitiated at a 25% dose reduction.
Če znova pride do klinično pomembne okužbe, je treba zdravljenje s klofarabinom prekiniti, dokler okužba ni klinično nadzorovana, nato pa se zdravljenje lahko nadaljuje z odmerkom, zmanjšanim za 25 %.
In the event of a sensitisation or severe local irritation from the use of retapamulin ointment, treatment should be discontinued, the ointment carefully wiped off, and appropriate alternative therapy for the infection instituted.
V primeru pojava preobčutljivosti ali hudega lokalnega draženja zaradi uporabe retapamulina v obliki mazila je treba zdravljenje prekiniti, mazilo previdno obrisati in uvesti primerno alternativno zdravljenje okužbe.
In the event of a suspected overdose, the appropriate supportive clinical care should be instituted, as dictated by the subject’s clinical status.
V primeru domnevnega prevelikega odmerjanja je treba uvesti ustrezno podporno klinično oskrbo, kot jo narekuje bolnikovo klinično stanje.
In the event of accidental contact with the mucous membranes, treat immediately by copious washing with water; medical attention should be sought.
Če pride do nenamernega stika z sluznicami, takoj izperite z veliko količino vode ter poiščite zdravniško pomoč.
In the event of accidental oral ingestion of TOBI Podhaler capsules, toxicity is unlikely as tobramycin is poorly absorbed from an intact gastrointestinal tract.
V primeru nehotenega zaužitja kapsule zdravila TOBI Podhaler je toksično delovanje le malo verjetno, saj se tobramicin slabo absorbira iz nepoškodovanih prebavil.
In the event of an accidental occupational exposure to Imlygic (e.g. through a splash to the eyes or mucous membranes) during preparation or administration, flush with clean water for at least 15 minutes.
V primeru nenamerne poklicne izpostavljenosti zdravilu Imlygic (npr. zaradi oškropitve oči ali sluznic) med pripravo ali dajanjem zdravila vsaj 15 minut izpirajte s čisto vodo.
In the event of an anaphylactic reaction, beta blockers (including eye drop preparations) may aggravate the reaction.
V primeru anafilaktične reakcije lahko beta blokatorji (vključno s kapljicami za oči) poslabšajo reakcijo.
In the event of an injection site related adverse reaction occuring, appropriate measures to manage these events should be taken (see section 4.8).
V primeru pojava neželenega učinka na mestu injiciranja, je za uravnavo teh učinkov potrebno izvesti ustrezne ukrepe (glejte poglavje 4.8).
In the event of an officially declared pandemic caused by the H5N1 strain of the influenza A, people who have already been vaccinated with Aflunov (with one or two doses) may be given only one more dose, instead of the two doses recommended for unvaccinated people.
V primeru uradno razglašene pandemije zaradi seva H5N1 gripe A lahko posamezniki, ki so že bili cepljeni s cepivom Aflunov (z enim ali dvema odmerkoma), prejmejo samo še en odmerek in ne dveh, kot se priporoča za ljudi, ki predhodno še niso bili cepljeni.
In the event of an overdose of Vokanamet, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the gastrointestinal tract, employ clinical monitoring, and institute clinical measures as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja zdravila Vokanamet je smiselno začeti z običajnimi podpornimi ukrepi, kot so odstranjevanje neabsorbiranega zdravila iz prebavil, klinično spremljanje bolnika in uvedba kliničnih ukrepov skladno z bolnikovo klinično sliko.
In the event of an overdose with OLYSIO, it is recommended to employ the usual supportive measures and observe the patient’s clinical status.
V primeru prevelikega odmerjanja zdravila OLYSIO se priporočajo splošni podporni ukrepi in spremljanje klinične slike bolnika.
In the event of an overdose, administration should be withheld and general supportive measures undertaken, including monitoring for arrhythmias, hypokalaemia and for signs and symptoms of fluid retention.
Če pride do prevelikega odmerjanja, je treba odmerjanje prekiniti in uvesti splošne podporne ukrepe, vključno s spremljanjem bolnika glede pojavljanja aritmij, hipokaliemije in znakov in simptomov zastajanja tekočin.
In the event of an overdose, appropriate supportive measures should be employed as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja je treba uvesti ustrezne podporne ukrepe, kot jih zahteva klinično stanje bolnika.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja je treba uvesti ustrezno podporno zdravljenje glede na bolnikovo klinično stanje.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja je treba uvesti ustrezno podporno zdravljenje kot ga narekuje bolnikovo klinično stanje.
In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja je treba uvesti ustrezno podporno zdravljenje, kot ga narekuje bolnikovo klinično stanje.
In the event of an overdose, consult your doctor, pharmacist or the nearest hospital immediately.
Če ste vzeli prevelik odmerek, se takoj posvetujte s svojim zdravnikom, farmacevtom ali najbližjo bolnišnico.
In the event of an overdose, further doses must be interrupted, and appropriate measures taken to assure that an adverse event has not occurred, i.e.
V primeru prevelikega odmerjanja je treba nadaljnjo uporabo zdravila prekiniti in ustrezno ukrepati za zagotovitev, da se ni pojavil kakšen neželeni učinek, tj.
In the event of an overdose, it is recommended that appropriate supportive treatment should be initiated as dictated by the patient’s clinical status.
V primeru prevelikega odmerjanja je priporočljivo uvesti ustrezno podporno terapijo, kot jo zahteva bolnikovo klinično stanje.
In the event of an overdose, physicians should follow general supportive measures and should treat symptomatically.
V primeru prevelikega odmerjanja je treba uporabiti splošne podporne ukrepe in simptomatsko zdravljenje.
In the event of an overdose, the following side effects were reported: flushing, headache, pruritus (itching), nausea, dizziness, vomiting, diarrhoea, abdominal pain/discomfort, and back pain.
V primeru prevelikega odmerjanja so poročali o naslednjih neželenih učinkih: zardevanje, glavobol, srbenje, siljenje na bruhanje, omotica, bruhanje, driska, bolečine/nelagodje v trebuhu, bolečine v hrbtu.
In the event of an overdose, the patient should be carefully monitored by the medical professional.
V primeru predoziranja mora bolnika skrbno nadzorovati zdravstveni delavec.
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).
V primeru prevelikega odmerka bortezomiba je treba spremljati bolnikove vitalne znake in uvesti ustrezne podporne ukrepe za vzdrževanje krvnega tlaka (npr.: tekočine, učinkovine, ki zvišujejo krvni tlak, in/ali inotropne učinkovine) in telesne temperature (glejte poglavji 4.2 in 4.4).
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).
V primeru prevelikega odmerka bortezomiboma je treba spremljati bolnikove vitalne znake in uvesti ustrezne podporne ukrepe za vzdrževanje krvnega tlaka (npr.: tekočine, učinkovine, ki zvišujejo krvni tlak, in/ali inotropne učinkovine) in telesne temperature (glejte poglavji 4.2 in 4.4).
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure (such as fluids, pressors, and/or inotropic agents) and body temperature (see sections 4.2 and 4.4).
V primeru prevelikega odmerka zdravila Velcade je treba spremljati bolnikove vitalne znake in uvesti ustrezne podporne ukrepe za vzdrževanje krvnega tlaka (npr.: tekočine, učinkovine, ki zvišujejo krvni tlak, in/ali inotropne učinkovine) in telesne temperature (glejte poglavji 4.2 in 4.4).
In the event of an overdose, the patient’s vital signs should be monitored and appropriate supportive care given to maintain blood pressure and respiratory status.
V primeru prevelikega odmerka je treba nadzirati življenjske znake bolnika in nuditi ustrezno podporno zdravljenje za vzdrževanje krvnega tlaka in stanje dihanja.
In the event of any damage to the vial, foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.
Če opazite kakršne koli poškodbe viale, če v cepivu opazite vidne delce in/ali drugo odstopanje od pričakovanega fizičnega izgleda, cepivo zavrzite.
In the event of blocked needle, the patients must follow the instructions described in Step 3 of the Instructions for Use accompanying the package leaflet (see section 4.2).
Če je igla zamašena, mora bolnik slediti navodilom, opisanim v 3. koraku navodila za uporabo, ki je priložen navodilu za uporabo (glejte poglavje 4.2).
In the event of bradycardia with poor haemodynamic tolerance, symptomatic treatment including intravenous beta- stimulating medicinal products such as isoprenaline may be considered.
Če imajo bolniki bradikardijo s slabim hemodinamičnim prenašanjem, razmislite o simptomatskem zdravljenju, vključno z intravenskimi spodbujevalci receptorjev beta, kot je izoprenalin.
In the event of contact, the area should be irrigated with plenty of water for at least 15 minutes.
V primeru stika izpirajte z obilo vode vsaj 15 minut.
In the event of contact, wash skin with soap and water.
V primeru stika operite kožo z vodo in milom.
In the event of contact, wash with clean water.
V primeru stika, takoj sperite s čisto vodo.
In the event of deterioration of COPD during treatment with Hirobriz Breezhaler, a re- evaluation of the patient and of the COPD treatment regimen should be undertaken.
Če pride med zdravljenjem z zdravilom Hirobriz Breezhaler do poslabšanja KOPB, je treba ponovno pregledati bolnika in oceniti shemo zdravljenja KOPB.
In the event of deterioration of COPD during treatment with Onbrez Breezhaler, a re- evaluation of the patient and of the COPD treatment regimen should be undertaken.
Če pride med zdravljenjem z zdravilom Onbrez Breezhaler do poslabšanja KOPB, je treba ponovno pregledati bolnika in oceniti shemo zdravljenja KOPB.
In the event of early regurgitation, identify the animal by matching the animal ID number with the number on the intraruminal device and re-administer an undamaged intraruminal device.
V primeru zgodnje regurgitacije določite žival tako, da primerjate identifikacijsko številko živali s številko intraruminalnega sistema in živali ponovno dajte nepoškodovani intraruminalni sistem.
In the event of either being observed (including rubber particles from the stopper), the vaccine should be discarded.
Če opazite eno ali drugo(vključno z delci gume iz zamaška), morate cepivo zavreči.
In the event of either being observed (including rubber particles from the stopper), the vaccine should be discarded.
Če opazite eno ali drugo(vključno z delci gume iz zamaška),, morate cepivo zavreči.
In the event of either being observed, discard the container.
Če opazite karkoli od navedenega, vsebnik zavrzite.
In the event of either being observed, discard the vaccine.
Če opazite kar koli od navedenega, morate cepivo zavreči.
In the event of fesoterodine overdose, treat with gastric lavage and give activated charcoal.
Pri prevelikem odmerjanju fesoterodina je treba bolnike zdraviti z izpiranjem želodca in aktivnim ogljem.
In the event of grade 2-4 acute toxicity, treatment must be discontinued immediately .
V primeru akutnih toksičnosti stopnje 2−4 je treba zdravljenje nemudoma prekiniti.